Patent US5580870A successfully refreshed from Google Patents.
← Back to Patent Explorer
US5580870A Expired / Lapsed US ⏱️ 0.0 years remaining

Quinazoline derivatives

Assignee: AstraZeneca UK Ltd
•
Filing: 1993-12-10
•
Granted: 1996-12-03
•
Expires: 2013-12-10
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract The invention concerns quinazoline derivatives of the formula I <IMAGE> I wherein m is 1, 2 or 3 and each R1 includes hydroxy, amino, ureido, hydroxyamino, trifluoromethoxy, (1-4C)alkyl, (1-4C)alkoxy and (1-3C)alkylenedioxy; and Q is a 9- or 10-membered bicyclic heterocyclic moiety containing one or two nitrogen heteroatoms and optionally containing a further heteroatom selected from nitrogen, oxygen and sulphur, or Q is a 9- or 10-membered bicyclic aryl moiety which heterocyclic or aryl moiety may optionally bear one or two substituents selected from halogeno, hydroxy, oxo, amino, nitro, carbamoyl, (1-4C)alkyl, (1-4C)alkoxy, (1-4C)alkylamino, di-[(1-4C)alkyl]amino and (2-4C)alkanoylamino; or a pharmaceutically-acceptable salt thereof; processes for their preparation; pharmaceutical compositions containing them; and the use of the receptor tyrosine kinase inhibitory properties of the compounds in the treatment of cancer.

Inventors

  • 👤 Andrew J. Barker
  • 👤 Dearg S. Brown

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-11-03 16:33
CPC Classifications
C; C07; C07D; C07D239/00; C07D239/70; C07D239/72; C07D239/86; C07D401/00; C07D401/02; C07D401/12; A; A61; A61P; A61P35/00; A61P43/00; C07D239/94; C07D403/00; C07D403/02; C07D403/12; C07D417/00; C07D417/02; C07D417/12; C07D491/00; C07D491/02; C07D491/04

Claims Analysis

Total Claims: 15
Claim 1
Independent Claim 171 words
A quinazoline derivative of the formula I ##STR6## wherein m is 1, 2 or 3 and each R 1 is independently hydroxy, amino, ureido, hydroxyamino, trifluoromethoxy, (1-4C)alkyl, (1-4C)alkoxy, (1-3C)alkylenedioxy, (1-4C)alkylamino, di-[(1-4C)alkyl]amino, pyrrolidin-1-yl, piperidino, morpholino, piperazin-1-yl, 4-(1-4C)alkylpiperazin-1-yl, (1-4C)alkylthio, halogeno-(1-4C)alkyl, hydroxy-(1-4C)alkyl, (2-4C)alkanoyloxy-(1-4C)alkyl, (1-4C)alkoxy-(1-4C)alkyl, cyano-(1-4C)alkyl, amino-(1-4C)alkyl, (1-4C)alkylamino-(1-4C)alkyl, di-[(1-4C)alkyl]amino-(1-4C)alkyl, piperidino-(1-4C)alkyl, morpholino-(1-4C)alkyl, piperazin-1-yl-(1-4C)alkyl, 4-(1-4C)alkylpiperazin-1-yl-(1-4C)alkyl, hydroxy-(2-4C)alkoxy-(1-4C)alkyl, (1-4C)alkoxy-(2-4C)alkoxy-(1-4C)alkyl, hydroxy-(2-4C)alkylamino-(1-4C)alkyl, (1-4C)alkoxy-(2-4C)alkylamino-(1-4C)alkyl, halogeno-(2-4C)alkoxy, hydroxy-(2-4C)alkoxy, (2-4C)alkanoyloxy-(2-4C)alkoxy, (1-4C)alkoxy-(2-4C)alkoxy, amino-(2-4C)alkoxy, (1-4C)alkylamino-(2-4C)alkoxy, di-[(1-4C)alkyl]amino-(2-4C)alkoxy, (2-4C)alkanoyloxy, hydroxy-(2-4C)alkanoyloxy, (1-4C)alkoxy-(2-4C)alkanoyloxy, phenyl-(1-4C)alkoxy, halogeno-(2-4C)alkylamino, hydroxy-(2-4C)alkylamino, (2-4C)alkanoyloxy-(2-4C)alkylamino, (1-4C)alkoxy-(2-4C)alkylamino, amino-(2-4C)alkylamino, (1-4C)alkylamino-(2-4C)alkylamino, di-[(1-4C)alkyl]amino-(2-4C)alkylamino, (2-4C)alkanoylamino, (1-4C)alkoxycarbonylamino, benzamido, 3-phenylureido, halogeno-(2-4C)alkanoylamino, hydroxy-(2-4C)alkanoylamino or (1-4C)alkoxy-(2-4C)alkanoylamino, and wherein said benzamido substituent or any phenyl group in a R 1 substituent may optionally bear one or two halogeno, (1-4C)alkyl or (1-4C)alkoxy substituents; and Q is a 9- or 10-membered bicyclic heterocyclic moiety, or a hydrogenated derivative thereof, containing one or two nitrogen heteroatoms and optionally containing a further heteroatom selected from nitrogen, oxygen and sulphur, which heterocyclic moiety, or a hydrogenated derivative thereof, may optionally bear one or two substituents selected from halogeno, hydroxy, oxo, amino, nitro, carbamoyl, (1-4C)alkyl, (1-4C)alkoxy, (1-4C)alkylamino, di-[(1-4C)alkyl]amino and (2-4C)alkanoylamino; or a pharmaceutically-acceptable salt thereof.
Claim 2
Dependent Claim 171 words
A quinazoline derivative of the formula I ##STR6## wherein m is 1, 2 or 3 and each R 1 is independently hydroxy, amino, ureido, hydroxyamino, trifluoromethoxy, (1-4C)alkyl, (1-4C)alkoxy, (1-3C)alkylenedioxy, (1-4C)alkylamino, di-[(1-4C)alkyl]amino, pyrrolidin-1-yl, piperidino, morpholino, piperazin-1-yl, 4-(1-4C)alkylpiperazin-1-yl, (1-4C)alkylthio, halogeno-(1-4C)alkyl, hydroxy-(1-4C)alkyl, (2-4C)alkanoyloxy-(1-4C)alkyl, (1-4C)alkoxy-(1-4C)alkyl, cyano-(1-4C)alkyl, amino-(1-4C)alkyl, (1-4C)alkylamino-(1-4C)alkyl, di-[(1-4C)alkyl]amino-(1-4C)alkyl, piperidino-(1-4C)alkyl, morpholino-(1-4C)alkyl, piperazin-1-yl-(1-4C)alkyl, 4-(1-4C)alkylpiperazin-1-yl-(1-4C)alkyl, hydroxy-(2-4C)alkoxy-(1-4C)alkyl, (1-4C)alkoxy-(2-4C)alkoxy-(1-4C)alkyl, hydroxy-(2-4C)alkylamino-(1-4C)alkyl, (1-4C)alkoxy-(2-4C)alkylamino-(1-4C)alkyl, halogeno-(2-4C)alkoxy, hydroxy-(2-4C)alkoxy, (2-4C)alkanoyloxy-(2-4C)alkoxy, (1-4C)alkoxy-(2-4C)alkoxy, amino-(2-4C)alkoxy, (1-4C)alkylamino-(2-4C)alkoxy, di-[(1-4C)alkyl]amino-(2-4C)alkoxy, (2-4C)alkanoyloxy, hydroxy-(2-4C)alkanoyloxy, (1-4C)alkoxy-(2-4C)alkanoyloxy, phenyl-(1-4C)alkoxy, halogeno-(2-4C)alkylamino, hydroxy-(2-4C)alkylamino, (2-4C)alkanoyloxy-(2-4C)alkylamino, (1-4C)alkoxy-(2-4C)alkylamino, amino-(2-4C)alkylamino, (1-4C)alkylamino-(2-4C)alkylamino, di-[(1-4C)alkyl]amino-(2-4C)alkylamino, (2-4C)alkanoylamino, (1-4C)alkoxycarbonylamino, benzamido, 3-phenylureido, halogeno-(2-4C)alkanoylamino, hydroxy-(2-4C)alkanoylamino or (1-4C)alkoxy-(2-4C)alkanoylamino, and wherein said benzamido substituent or any phenyl group in a R 1 substituent may optionally bear one or two halogeno, (1-4C)alkyl or (1-4C)alkoxy substituents; and Q is a 9- or 10-membered bicyclic heterocyclic moiety, or a hydrogenated derivative thereof, containing one or two nitrogen heteroatoms and optionally containing a further heteroatom selected from nitrogen, oxygen and sulphur, which heterocyclic moiety, or a hydrogenated derivative thereof, may optionally bear one or two substituents selected from halogeno, hydroxy, oxo, amino, nitro, carbamoyl, (1-4C)alkyl, (1-4C)alkoxy, (1-4C)alkylamino, di-[(1-4C)alkyl]amino and (2-4C)alkanoylamino; or a pharmaceutically-acceptable salt thereof.
Claim 3
Dependent Claim 184 words
A quinazoline derivative of the formula I ##STR7## wherein m is 1, 2 or 3 and each R 1 is independently hydrogen, halogeno, nitro, hydroxy, amino, ureido, hydroxyamino, trifluoromethoxy, (1-4C)alkyl, (1-4C)alkoxy, (1-3C)alkylenedioxy, (1-4C)alkylamino, di-[1-4C)alkyl]amino, pyrrolidin-1-yl, piperidino, morpholino, piperazin-1-yl, 4-(1-4C)alkylpiperazin-1-yl, (1-4C)alkylthio, halogeno-(1-4C)alkyl, hydroxy-(1-4C)alkyl, (2-4C)alkanoyloxy-(1-4C)alkyl, (1-4C)alkoxy-(1-4C)alkyl, cyano-(1-4C)alkyl, amino-1-4C)alkyl, (1-4C)alkylamino-(1-4C)alkyl, di [(1-4C)alkyl ]amino-(1-4C)alkyl, piperidino-(1-4C)alkyl, morpholino-(1-4C)alkyl, piperazin-1-yl (1-4C)alkyl, 4-(1-4C)alkylpiperazin-1-yl-(1-4C)alkyl, hydroxy-(2-4C)alkoxy-(1-4C)alkyl, (1-4C)alkoxy(2-4C)alkoxy-(1-4C)alkyl, hydroxy-(2-4C)alkylamino-(1-4C)alkyl, (1-4C)alkoxy-(2-4C)alkylamino-(1-4C)alkyl, halogeno-(2-4C)alkoxy, hydroxy-(2-4C)alkoxy, (2-4C)alkanoyloxy-(2-4C)alkoxy, (1-4C)alkoxy-(2-4C)alkoxy, amino-(2-4C)alkoxy, (1-4C)alkylamino-(2-4C)alkoxy, di-[(1-4C)alkyl]amino-(2-4C)alkoxy, (2-4C)alkanoyloxy, hydroxy-(2-4C)alkanoyloxy, (1-4C)alkoxy-(2-4C)alkanoyloxy, phenyl-(1-4C)alkoxy, halogeno-(2-4C)alkylamino, hydroxy-(2-4C)alkylamino, (2-4C)alkanoyloxy-(2-4C)alkylamino, (1-4C)alkoxy-(2-4C)alkylamino, amino-(2-4C)alkylamino, (1-4C)alkylamino-(2-4C)alkylamino, di-[(1-4C)alkyl]amino-(2-4C)alkylamino, (2-4C)alkanoylamino, (1-4C)alkoxycarbonylamino, benzamido, 3-phenylureido, halogeno-(2-4C)alkanoylamino, hydroxy-(2-4C)alkanoylamino or (1-4C)alkoxy-(2-4C)alkanoylamino, and wherein said benzamido substituent or any phenyl group in a R 1 substituent may optionally bear one or two halogeno, (1-4C)alkyl or (1-4C)alkoxy substituents; and Q is a 9- or 10-membered bicyclic heterocyclic moiety, or a hydrogenated derivative thereof, containing one or two nitrogen heteroatoms and optionally containing a further heteroatom selected from nitrogen, oxygen and sulphur, which heterocyclic moiety, or a hydrogenated derivative thereof, may optionally bear one or two substituents selected from carboxy, (1-4C)alkoxycarbonyl, halogeno, hydroxy, oxo, amino, nitro, carbamoyl, (1-4C)alkyl, (1-4C)alkoxy, (1-4C)alkylamino, di-[(1-4C)alkyl]amino and (2-4C)alkanoylamino; or a pharmaceutically-acceptable salt thereof; except that 4-(4-quinazolinylamino)quinazoline is excluded.
Claim 4
Dependent Claim 184 words
A quinazoline derivative of the formula I ##STR7## wherein m is 1, 2 or 3 and each R 1 is independently hydrogen, halogeno, nitro, hydroxy, amino, ureido, hydroxyamino, trifluoromethoxy, (1-4C)alkyl, (1-4C)alkoxy, (1-3C)alkylenedioxy, (1-4C)alkylamino, di-[1-4C)alkyl]amino, pyrrolidin-1-yl, piperidino, morpholino, piperazin-1-yl, 4-(1-4C)alkylpiperazin-1-yl, (1-4C)alkylthio, halogeno-(1-4C)alkyl, hydroxy-(1-4C)alkyl, (2-4C)alkanoyloxy-(1-4C)alkyl, (1-4C)alkoxy-(1-4C)alkyl, cyano-(1-4C)alkyl, amino-1-4C)alkyl, (1-4C)alkylamino-(1-4C)alkyl, di [(1-4C)alkyl ]amino-(1-4C)alkyl, piperidino-(1-4C)alkyl, morpholino-(1-4C)alkyl, piperazin-1-yl (1-4C)alkyl, 4-(1-4C)alkylpiperazin-1-yl-(1-4C)alkyl, hydroxy-(2-4C)alkoxy-(1-4C)alkyl, (1-4C)alkoxy(2-4C)alkoxy-(1-4C)alkyl, hydroxy-(2-4C)alkylamino-(1-4C)alkyl, (1-4C)alkoxy-(2-4C)alkylamino-(1-4C)alkyl, halogeno-(2-4C)alkoxy, hydroxy-(2-4C)alkoxy, (2-4C)alkanoyloxy-(2-4C)alkoxy, (1-4C)alkoxy-(2-4C)alkoxy, amino-(2-4C)alkoxy, (1-4C)alkylamino-(2-4C)alkoxy, di-[(1-4C)alkyl]amino-(2-4C)alkoxy, (2-4C)alkanoyloxy, hydroxy-(2-4C)alkanoyloxy, (1-4C)alkoxy-(2-4C)alkanoyloxy, phenyl-(1-4C)alkoxy, halogeno-(2-4C)alkylamino, hydroxy-(2-4C)alkylamino, (2-4C)alkanoyloxy-(2-4C)alkylamino, (1-4C)alkoxy-(2-4C)alkylamino, amino-(2-4C)alkylamino, (1-4C)alkylamino-(2-4C)alkylamino, di-[(1-4C)alkyl]amino-(2-4C)alkylamino, (2-4C)alkanoylamino, (1-4C)alkoxycarbonylamino, benzamido, 3-phenylureido, halogeno-(2-4C)alkanoylamino, hydroxy-(2-4C)alkanoylamino or (1-4C)alkoxy-(2-4C)alkanoylamino, and wherein said benzamido substituent or any phenyl group in a R 1 substituent may optionally bear one or two halogeno, (1-4C)alkyl or (1-4C)alkoxy substituents; and Q is a 9- or 10-membered bicyclic heterocyclic moiety, or a hydrogenated derivative thereof, containing one or two nitrogen heteroatoms and optionally containing a further heteroatom selected from nitrogen, oxygen and sulphur, which heterocyclic moiety, or a hydrogenated derivative thereof, may optionally bear one or two substituents selected from carboxy, (1-4C)alkoxycarbonyl, halogeno, hydroxy, oxo, amino, nitro, carbamoyl, (1-4C)alkyl, (1-4C)alkoxy, (1-4C)alkylamino, di-[(1-4C)alkyl]amino and (2-4C)alkanoylamino; or a pharmaceutically-acceptable salt thereof; except that 4-(4-quinazolinylamino)quinazoline is excluded.
Claim 5
Dependent Claim 186 words
A quinazoline derivative of the formula I ##STR8## wherein M is 1, 2 or 3 and each R 1 is independently hydrogen, halogeno, nitro, hydroxy, amino, ureido, hydroxyamino, trifluoromethoxy, (1-4C)alkyl, (1-4C)alkoxy, (1-3C)alkylenedioxy, (1-4C)alkylamino, di-[1-4C)alkyl]amino, pyrrolidin-1-yl, piperidino, morpholino, piperazin-1-yl, 4-(1-4C)alkylpiperazin-1-yl, (1-4C)alkylthio, halogeno-(1-4C)alkyl, hydroxy-(1-4C)alkyl, (2-4C)alkanoyloxy-(1-4C)alkyl, (1-4C)alkoxy-(1-4C)alkyl, cyano-(1-4C)alkyl, amino-1-4C)alkyl, (1-4C)alkylamino-(1-4C)alkyl, di[(1-4C)alkyl]amino-(1-4C)alkyl, piperidino-(1-4C)alkyl, morpholino-(1-4C)alkyl, piperazin-1-yl-(1-4C)alkyl, 4-(1-4C)alkylpiperazin-1-yl-(1-4C)alkyl, hydroxy-(2-4C)alkoxy-(1-4C)alkyl, (1-4C)alkoxy-(2-4C)alkoxy-(1-4C)alkyl, hydroxy-(2-4C)alkylamino-(1-4C)alkyl, (1-4C)alkoxy-(2-4C)alkylamino-(1-4C)alkyl, halogeno-(2-4C)alkoxy, hydroxy-(2-4C)alkoxy, (2-4C)alkanoyloxy-(2-4C)alkoxy, (1-4C)alkoxy-(2-4C)alkoxy, amino-(2-4C)alkoxy, (1-4C)alkylamino-(2-4C)alkoxy, di-[(1-4C)alkyl]amino-(2-4C)alkoxy, (2-4C)alkanoyloxy, hydroxy-(2-4C)alkanoyloxy, (1-4C)alkoxy-(2-4C)alkanoyloxy, phenyl-(1-4C)alkoxy, halogeno-(2-4C)alkylamino, hydroxy-(2-4C)alkylamino, (2-4C)alkanoyloxy-(2-4C)alkylamino, (1-4C)alkoxy-(2-4C)alkylamino, amino-(2 -4C)alkylamino, (1-4C)alkylamino-(2 -4C)alkylamino, di-[(1-4C)alkyl]amino-(2-4C)alkylamino, (2-4C)alkanoylamino, (1-4C)alkoxycarbonylamino, benzamido, 3-phenylureido, halogeno-(2-4C)alkanoylamino, hydroxy-(2-4C)alkanoylamino, (1-4C)alkoxy-(2-4C)alkanoylamino, 2-oxopyrrolidin-1-yl or 2-oxopiperidin-1-yl, and wherein said benzamido substituent or any phenyl group in a R 1 substituent may optionally bear one or two halogeno, (1-4C)alkyl or (1-4C)alkoxy substituents; and Q is a 9- or 10-membered bicyclic heterocyclic moiety, or a hydrogenated derivative thereof, containing one or two nitrogen heteroatoms and optionally containing a further heteroatom selected from nitrogen, oxygen and sulphur, which heterocyclic moiety, or a hydrogenated derivative thereof, may optionally bear one or two substituents selected from cyano, carboxy, (1-4C)alkoxycarbonyl, halogeno, hydroxy, oxo, amino, nitro, carbamoyl, (1-4C)alkyl, (1-4C)alkoxy, (1-4C)alkylamino, di-[(1-4C)alkyl]amino and (2-4C)alkanoylamino; or a pharmaceutically-acceptable salt thereof; except that 4-(4-quinazolinylamino)quinazoline is excluded.
Claim 6
Dependent Claim 186 words
A quinazoline derivative of the formula I ##STR8## wherein M is 1, 2 or 3 and each R 1 is independently hydrogen, halogeno, nitro, hydroxy, amino, ureido, hydroxyamino, trifluoromethoxy, (1-4C)alkyl, (1-4C)alkoxy, (1-3C)alkylenedioxy, (1-4C)alkylamino, di-[1-4C)alkyl]amino, pyrrolidin-1-yl, piperidino, morpholino, piperazin-1-yl, 4-(1-4C)alkylpiperazin-1-yl, (1-4C)alkylthio, halogeno-(1-4C)alkyl, hydroxy-(1-4C)alkyl, (2-4C)alkanoyloxy-(1-4C)alkyl, (1-4C)alkoxy-(1-4C)alkyl, cyano-(1-4C)alkyl, amino-1-4C)alkyl, (1-4C)alkylamino-(1-4C)alkyl, di[(1-4C)alkyl]amino-(1-4C)alkyl, piperidino-(1-4C)alkyl, morpholino-(1-4C)alkyl, piperazin-1-yl-(1-4C)alkyl, 4-(1-4C)alkylpiperazin-1-yl-(1-4C)alkyl, hydroxy-(2-4C)alkoxy-(1-4C)alkyl, (1-4C)alkoxy-(2-4C)alkoxy-(1-4C)alkyl, hydroxy-(2-4C)alkylamino-(1-4C)alkyl, (1-4C)alkoxy-(2-4C)alkylamino-(1-4C)alkyl, halogeno-(2-4C)alkoxy, hydroxy-(2-4C)alkoxy, (2-4C)alkanoyloxy-(2-4C)alkoxy, (1-4C)alkoxy-(2-4C)alkoxy, amino-(2-4C)alkoxy, (1-4C)alkylamino-(2-4C)alkoxy, di-[(1-4C)alkyl]amino-(2-4C)alkoxy, (2-4C)alkanoyloxy, hydroxy-(2-4C)alkanoyloxy, (1-4C)alkoxy-(2-4C)alkanoyloxy, phenyl-(1-4C)alkoxy, halogeno-(2-4C)alkylamino, hydroxy-(2-4C)alkylamino, (2-4C)alkanoyloxy-(2-4C)alkylamino, (1-4C)alkoxy-(2-4C)alkylamino, amino-(2 -4C)alkylamino, (1-4C)alkylamino-(2 -4C)alkylamino, di-[(1-4C)alkyl]amino-(2-4C)alkylamino, (2-4C)alkanoylamino, (1-4C)alkoxycarbonylamino, benzamido, 3-phenylureido, halogeno-(2-4C)alkanoylamino, hydroxy-(2-4C)alkanoylamino, (1-4C)alkoxy-(2-4C)alkanoylamino, 2-oxopyrrolidin-1-yl or 2-oxopiperidin-1-yl, and wherein said benzamido substituent or any phenyl group in a R 1 substituent may optionally bear one or two halogeno, (1-4C)alkyl or (1-4C)alkoxy substituents; and Q is a 9- or 10-membered bicyclic heterocyclic moiety, or a hydrogenated derivative thereof, containing one or two nitrogen heteroatoms and optionally containing a further heteroatom selected from nitrogen, oxygen and sulphur, which heterocyclic moiety, or a hydrogenated derivative thereof, may optionally bear one or two substituents selected from cyano, carboxy, (1-4C)alkoxycarbonyl, halogeno, hydroxy, oxo, amino, nitro, carbamoyl, (1-4C)alkyl, (1-4C)alkoxy, (1-4C)alkylamino, di-[(1-4C)alkyl]amino and (2-4C)alkanoylamino; or a pharmaceutically-acceptable salt thereof; except that 4-(4-quinazolinylamino)quinazoline is excluded.
Claim 7
Dependent Claim 104 words
A quinazoline derivative of the formula I as claimed in claim 1 or claim 2 wherein m is 1, 2 or 3 and each R 1 is independently hydroxy, amino, fluoro, chloro, nitro, methyl, ethyl, methoxy, ethoxy, propoxy, isopropoxy, butoxy, methylenedioxy, ethylenedioxy, methylamino, ethylamino, dimethylamino, diethylamino, pyrrolidin-1-yl, piperidino, morpholino, piperazin-1-yl, 4-methylpiperazin-1-yl, methylthio, ethylthio, acetamido, propionamido or 2-chloroacetamido; and Q is indolyl, 1H-benzimidazolyl, 1H-indazolyl, benzoxazolyl, benzothiazolyl, 1H-benzotriazolyl, benzo[c]furazanyl, benzo[c][2,1,3]thiadiazolyl, quinolyl, isoquinolyl, cinnolinyl, quinazolinyl or, quinoxalinyl, which may optionally bear one or two substituents selected from fluoro, chloro, hydroxy, amino, carboxy, methyl, ethyl, methoxy, ethoxy, methylamino, dimethylamino, acetamido, methoxycarbonyl and ethoxycarbonyl; or a pharmaceutically-acceptable salt thereof.
Claim 8
Dependent Claim 140 words
A quinazoline derivative of the formula I as claimed in claim 1 or claim 2 wherein (R 1 ) m is 6-hydroxy, 7-hydroxy, 6,7-dihydroxy, 6-amino, 7-amino, 6-fluoro, 7-fluoro, 6-chloro, 7-chloro, 6-nitro, 6-methoxy, 7-methoxy, 6,7-dimethoxy, 6,7-diethoxy, 6-hydroxy-7-methoxy, 6,7-methylenedioxy, 6,7-ethylenedioxy, 6-methylamino, 7-methylamino, 6-ethylamino, 6-dimethylamino, 7-dimethylamino, 6-diethylamino, 6-pyrrolidin-1-yl, 7-pyrrolidin-1-yl, 6-piperidino, 7-piperidino, 6-morpholino, 7-morpholino, 6-piperazin-1-yl, 7-piperazin-1-yl, 6-(4-methylpiperazin-1-yl), 7-(4-methylpiperazin-1-yl), 6-methylthio, 7-methylthio, 6-amino-7-methoxy, 6-amino-7-methylamino, 6-acetamido, 7-acetamido, 6-(2-chloroacetamido) or 7-(2-chloroacetamido); and Q is 4-, 5- or 6-indolyl, 1H-benzimidazol-4-yl, 1H-benzimidazol-5-yl, 1H-benzimidazol-6-yl, 1H-indazol-4-yl, 1H-indazol-5-yl, 1H-indazol-6-yl, 1H-indazol-7-yl, 5- or 6-benzoxazolyl, 5- or 6-benzothiazolyl, 1H-benzotriazol-4-yl, 1H-benzotriazol-5-yl, 1H-benzotriazol-6-yl, benzo[c][2,1,3]thiadiazol-4-yl, 2-, 3-, 4-, 5-, 6-, 7- or 8-quinolyl, 1-, 3-, 4-, 5-, 6-, 7- or 8-isoquinolyl, 4-, 5-, 6-, 7- or 8-cinnolinyl, 5-, 6-, 7- or 8-quinazolinyl or 2-, 5- or 6-quinoxalinyl, which may optionally bear one or two substituents selected from fluoro, chloro, methyl, ethyl and methoxy; or a pharmaceutically-acceptable salt thereof.
Claim 9
Dependent Claim 42 words
A quinazoline derivative of the formula I as claimed in claim 1 wherein (R 1 ) m is 6-amino, 6,7-dimethoxy, 6-piperidino or 6-acetamido; and Q is 5-indolyl, 1H-indazol-5-yl, 6-benzothiazolyl, 1H-benzotriazol-5-yl, benzo[c][2,1,3]thiadiazol-4-yl, 5-quinolyl, 6-quinolyl, 8-quinolyl, 5-isoquinolyl or 5-quinoxalinyl; or a pharmaceutically-acceptable salt thereof.
Claim 10
Dependent Claim 28 words
A quinazoline derivative of the formula I as claimed in claim 1 selected from: 6,7-dimethoxy-4-(5-quinolylamino)quinazoline, 6,7-dimethoxy-4-(6-quinolylamino)quinazoline, 6,7-dimethoxy-4-(5-isoquinolylamino)quinazoline, 6,7-dimethoxy-4-(5-indolylamino)quinazoline, 6,7-dimethoxy-4-[(1H-indazol-5-yl)amino]quinazoline, 4-(6-benzothiazolylamino)-6,7-dimethoxyquinazoline and 4-[(benzo[c][2,1,3]thiadiazol-4-yl)amino]-6,7-dimethoxyquinazoline; or a pharmaceutically-acceptable acid-addition salt thereof.
Claim 11
Dependent Claim 33 words
A pharmaceutical composition which comprises a quinazoline derivative of the formula I, or a pharmaceutically-acceptable salt thereof, as claimed in any one of claims 1-7 in association with a pharmaceutically-acceptable diluent or carrier.
Claim 12
Independent Claim 57 words
A method for producing an anti-cancer effect in a warm-blooded animal having a cancer which is sensitive to inhibition of the EGF-type of receptor tyrosine kinase enzymes which comprises administering to said animal an effective amount of a quinazoline derivative of the formula I, or a pharmaceutically-acceptable salt thereof, as claimed in any one of claims 4-7.
Claim 13
Independent Claim 57 words
A method for producing an anti-proliferative effect in a warm-blooded animal having a cancer which is sensitive to inhibition of the EGF-type of receptor tyrosine kinase enzymes which comprises administering to said animal an effective amount of a quinazoline derivative of the formula I, or a pharmaceutically-acceptable salt thereof, as claimed in any one of claims 4-7.
Claim 14
Independent Claim 58 words
A method for aiding the regression or palliation in a warm-blooded animal of a cancer which is sensitive to inhibition of the EGF-type of receptor tyrosine kinase enzymes which comprises administering to said animal an effective amount of a quinazoline derivative of the formula I, or a pharmaceutically-acceptable salt thereof, as claimed in any one of claims 4-7.
Claim 15
Independent Claim 49 words
A method for producing in a warm-blooded animal an inhibitory effect against the EGF-type of receptor tyrosine kinase enzymes which comprises administering to said animal an effective amount of a quinazoline derivative of the formula I, or a pharmaceutically-acceptable salt thereof, as claimed in any one of claims 4-7.

References Cited (Backward Citations)

US3470182A Cited
WO1992014716A1 Cited
WO1992020642A1 Cited
EP0520722A1 Cited
EP0566226A1 Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1999-12-03 2000-06-03 2000-12-03 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 2003-12-03 2004-06-03 2004-12-03 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 2007-12-03 2008-06-03 2008-12-03 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag